Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results.

Saved in:
Bibliographic Details
Title: Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results.
Authors: Biller BMK; Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA., Gilis-Januszewska A; Department of Endocrinology, Jagiellonian University, Medical College, 30-688 Kraków, Poland., Doknic M; University Clinical Center of Serbia, Medical Faculty University, 11000 Belgrade, Serbia., Pico AM; Clinical Medicine, Alicante Institute for Health and Biomedical Research (ISABIAL), 03202 Elche, Alicante, Spain., Fleseriu M; Department of Medicine and Neurological Surgery, Pituitary Center, Oregon Health and Science University, Portland, OR 97239, USA., Raverot G; Department of Endocrinology, Hospices Civils de Lyon, 69 500 Lyon Cedex 03, France., Isidori AM; Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, Italy., Takahashi Y; Nara Medical University, Department of Diabetes and Endocrinology, Kashihara, Nara 634-8521, Japan., Garcia JM; Department of Medicine, University of Washington/GRECC, Puget Sound VA, Seattle, WA 98108, USA., Silverstein JM; Division of Endocrinology, Metabolism & Lipid Research, Washington University School of Medicine, St Louis, MO 63110, USA., Bancos I; Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN 55902, USA., Fukuoka H; Division of Diabetes and Endocrinology, Kobe University Hospital, Kobe 650-0017, Japan., Huang E; Endocrine and Rare Disease Medical Sciences, Ascendis Pharma, Inc., Palo Alto, CA 94304, USA., Kang J; Endocrine and Rare Disease Medical Sciences, Ascendis Pharma, Inc., Palo Alto, CA 94304, USA., Komirenko AS; Endocrine and Rare Disease Medical Sciences, Ascendis Pharma, Inc., Palo Alto, CA 94304, USA., Domrzalski L; Endocrine and Rare Disease Medical Sciences, Ascendis Pharma, Inc., Palo Alto, CA 94304, USA., Shu AD; Endocrine and Rare Disease Medical Sciences, Ascendis Pharma, Inc., Palo Alto, CA 94304, USA., Beckert M; Endocrine and Rare Disease Medical Sciences, Ascendis Pharma A/S, 2900 Hellerup, Denmark., Yuen KCJ; Department of Neuroendocrinology and Neurosurgery, Barrow Neurological Institute, University of Arizona College of Medicine and Creighton University School of Medicine, Phoenix, AZ 85013, USA.
Source: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2026 May 19; Vol. 111 (6), pp. 1640-1650.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1945-7197
DOI:10.1210/clinem/dgaf680